These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26164850)

  • 1. Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.
    Nishizawa T; Taniura T; Nomura S
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):887-92. PubMed ID: 26164850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
    Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
    Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
    Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
    Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
    Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
    Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
    Hirai T; Kimura T; Echizen H
    Biol Pharm Bull; 2016; 39(6):1013-21. PubMed ID: 27251504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
    Tani S; Nagao K; Hirayama A
    Clin Drug Investig; 2015 Dec; 35(12):823-31. PubMed ID: 26482071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study.
    Takeshita M; Tanaka A; Yoshida H; Nakamura I; Shibata Y; Hata S; Kushiyama A; Okutsu M; Ishizu T; Node K
    J Atheroscler Thromb; 2024 Jun; 31(6):864-875. PubMed ID: 38220209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Kamatani N; Hosoya T
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
    Baek CH; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2018 Aug; 16(4):401-406. PubMed ID: 29251581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
    Yamamoto T; Hidaka Y; Inaba M; Ishimura E; Ooyama H; Kakuda H; Moriwaki Y; Higami K; Ohtawara A; Hosoya T; Nishikawa H; Taniguchi A; Ueda T; Yamauchi T; Fujimori S; Mineo I; Yamanaka H
    Mod Rheumatol; 2015 Sep; 25(5):779-83. PubMed ID: 25671406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Febuxostat Therapy on Circulating Adipokine Profiles in Patients with Overweight or Obesity and Asymptomatic Hyperuricemia: A Randomized Controlled Study.
    Dong M; Cui Z; Liu Y; Bu Y; An K; Mao L
    Obes Facts; 2024; 17(5):524-534. PubMed ID: 39116844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients.
    Pichholiya M; Yadav AK; Luhadia SK; Tahashildar J; Aseri ML
    Indian J Pharmacol; 2016; 48(5):522-525. PubMed ID: 27721537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
    Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.